Sign In
Buy GKOS
$113.64
+2.86 (+2.58%)
At Close: Jun 03, 2026
Glaukos Announces Third Quarter 2025 Financial Results
04:05pm, Wednesday, 29'th Oct 2025
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
Will Glaukos (GKOS) Report Negative Earnings Next Week? What You Should Know
11:06am, Wednesday, 22'nd Oct 2025
Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
US FDA approves Glaukos' new eye therapy
07:10am, Monday, 20'th Oct 2025
The U.S. Food and Drug Administration has approved a new eye therapy from Glaukos Corp , giving patients a less painful and more convenient option to treat a progressive condition that can severely af
Glaukos Announces FDA Approval of Epioxa™
07:00am, Monday, 20'th Oct 2025
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting
07:00am, Tuesday, 14'th Oct 2025
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29
07:00am, Wednesday, 08'th Oct 2025
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
Glaukos Breaks Ground on New Research, Development, and Manufacturing Facility in Huntsville, Alabama
04:05pm, Thursday, 25'th Sep 2025
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
Glaukos Builds Dual Growth Engines Amid Market Headwinds
11:11am, Tuesday, 02'nd Sep 2025
GKOS raises revenue guidance after record 1H sales, fueled by iDose TR adoption and expanding international glaucoma momentum.
Glaukos Announces Participation in Wells Fargo Healthcare Conference
07:00am, Wednesday, 13'th Aug 2025
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
Glaukos (GKOS) Q2 Revenue Jumps 30%
01:54am, Friday, 01'st Aug 2025
Glaukos (GKOS -8.55%), a medical technology company focused on novel ophthalmic therapies, announced its financial results for the second quarter on July 30, 2025. The company reported GAAP revenue of
GKOS Stock Falls Despite Q2 Earnings & Revenues Beat, Guidance Raised
02:31pm, Thursday, 31'st Jul 2025
Glaukos' second-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern.
Glaukos Corporation (GKOS) Q2 2025 Earnings Call Transcript
05:15am, Thursday, 31'st Jul 2025
Glaukos Corporation (NYSE:GKOS ) Q2 2025 Earnings Conference Call July 30, 2025 4:30 PM ET Company Participants Alex R. Thurman - Senior VP & CFO Christopher William Lewis - Vice President of Investor
Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates
06:46pm, Wednesday, 30'th Jul 2025
Glaukos (GKOS) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.52 per share a year ago.
Glaukos Announces Second Quarter 2025 Financial Results
04:05pm, Wednesday, 30'th Jul 2025
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
Glaukos Ramps Up iDose TR, Battles Legacy and Reimbursement Risks
09:20am, Wednesday, 09'th Jul 2025
GKOS posts record Q1 on iDose TR strength, but reimbursement hurdles and legacy declines may hurt its near-term outlook.
